Skip to main content

Table 1 Corticosteroid exposure post-randomization, modified intention-to-treat population

From: Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial

  Placebo Atacicept 75 mg Atacicept 150 mg
  ( n = 154) ( n = 157) ( n = 144)
Zero dose increases, n (%) 108 (70.1) 115 (73.2) 122 (85.3)
  (n = 154) (n = 157) (n = 143)
Corticosteroids ≥20 mg/day, n (%) 43 (27.9) 39 (24.8) 17 (11.9)
Odds ratio   0.860 0.346
P value   0.563 0.001